RenovoRx Inc. (RNXT)
NASDAQ: RNXT
· Real-Time Price · USD
0.98
-0.26 (-20.97%)
At close: Aug 15, 2025, 12:54 PM
-20.97% (1D)
| Bid | 0.98 |
| Market Cap | 36.02M |
| Revenue (ttm) | 240K |
| Net Income (ttm) | -10.16M |
| EPS (ttm) | -0.41 |
| PE Ratio (ttm) | -2.4 |
| Forward PE | -3.42 |
| Analyst | Strong Buy |
| Ask | 0.99 |
| Volume | 832,643 |
| Avg. Volume (20D) | 200,388 |
| Open | 1.00 |
| Previous Close | 1.24 |
| Day's Range | 0.90 - 1.03 |
| 52-Week Range | 0.75 - 1.69 |
| Beta | 1.26 |
About RNXT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol RNXT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for RNXT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
RenovoRx Inc. is scheduled to release its earnings on
Nov 12, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 hours ago
RenovoRx shares are trading lower following the re...
Unlock content with
Pro Subscription
6 months ago
-20.55%
RenovoRx shares are trading lower after the company announced the pricing of a $12.1 million underwritten public offering of 11,523,810 shares at $1.05 per share.
3 months ago · seekingalpha.com
RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call TranscriptRenovoRx, Inc. (NASDAQ:RNXT ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Valter Pinto - IR Ramtin Agah - Founder and Chief Medical Officer Shaun Bagai - CEO Ronald K...
3 months ago · businesswire.com
RenovoRx Reports First Quarter 2025 Financial Results and Business HighlightsMOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing Renov...